Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of …
S Amadori, S Suciu, D Selleslag, F Aversa… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a …
S Amadori, S Suciu, R Stasi, HR Salih… - Journal of clinical …, 2013 - ascopubs.org
Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
AK Burnett, NH Russell, RK Hills, J Kell… - Journal of clinical …, 2012 - ascopubs.org
Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
B Löwenberg, J Beck, C Graux… - Blood, The Journal …, 2010 - ashpublications.org
In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained
one of the major therapeutic challenges, with more than 75% relapses after complete …
one of the major therapeutic challenges, with more than 75% relapses after complete …
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid …
AK Burnett, RK Hills, AE Hunter, D Milligan, WJ Kell… - Leukemia, 2013 - nature.com
The treatment of older patients with acute myeloid leukaemia, who are not considered
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …
[HTML][HTML] Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
J Lambert, C Pautas, C Terré, E Raffoux, P Turlure… - …, 2019 - ncbi.nlm.nih.gov
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of
gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves …
gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves …
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from …
RK Hills, S Castaigne, FR Appelbaum… - The lancet …, 2014 - thelancet.com
Background Gemtuzumab ozogamicin was the first example of antibody-directed
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a …
S Amadori, S Suciu, R Stasi, R Willemze, F Mandelli… - Leukemia, 2005 - nature.com
The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
AK Burnett, RK Hills, D Milligan, L Kjeldsen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
SH Petersdorf, KJ Kopecky, M Slovak… - Blood, The Journal …, 2013 - ashpublications.org
This randomized phase 3 clinical trial evaluated the potential benefit of the addition of
gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in …
gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in …
相关搜索
- induction chemotherapy gemtuzumab ozogamicin
- older patients intensive chemotherapy
- randomized phase intensive chemotherapy
- older patients randomized phase
- eortc gimema intensive chemotherapy
- older patients eortc gimema
- multicenter phase gemtuzumab ozogamicin
- meta analysis gemtuzumab ozogamicin
- randomized phase eortc gimema
- safety updates gemtuzumab ozogamicin
- postremission treatment gemtuzumab ozogamicin
- open label gemtuzumab ozogamicin
- older patients gemtuzumab ozogamicin
- older patients induction chemotherapy
- identification of patients gemtuzumab ozogamicin
- younger patients gemtuzumab ozogamicin